Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bomedemstat in Essential Thrombocythemia
NCT04254978Phase 2Completed
- Sponsor
- Imago BioSciences, Inc.
- Start
- Sep 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of bomedemstat in essential thrombocythemia (ET), sponsored by Imago BioSciences, Inc. Primary endpoints: Number of Participants Who Experienced an Adverse Event at 30 months, Number of Participants Who Discontinued Study Treatment Due to an AE at 28 months and 1 more. Started Sep 2020; status: completed.
02
Drugs
bomedemstat
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT04254978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04254978.